PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE: **NEW ASSIGNMENT** NATURE OF CONVEYANCE: **ASSIGNMENT**

CONVEYING PARTY DATA

Name	Execution Date
Ulf Landegren	12/11/2006

RECEIVING PARTY DATA

Name:	Landegren Gene Technology AB	
Street Address:	Idress: Rudbecklaboratory	
City:	Uppsala	
State/Country:	SWEDEN	
Postal Code:	751 85	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	10495895

CORRESPONDENCE DATA

Fax Number: (513)421-0991

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 5133694224

Email: hkozlowski@porterwright.com

Correspondent Name: Holly D. Kozlowski Address Line 1: 41 South High Street

Address Line 2: Porter Wright Morris & Arthur LLP

Address Line 4: Columbus, OHIO 43215

ATTORNEY DOCKET NUMBER: 3995937-174117

NAME OF SUBMITTER: Holly D. Kozlowski

Total Attachments: 5

500735424

source=LandegrenAssignment#page1.tif source=LandegrenAssignment#page2.tif source=LandegrenAssignment#page3.tif source=LandegrenAssignment#page4.tif

REEL: 022003 FRAME: 0379

PATENT

source=LandegrenAssignment#page5.tif

CONFIRMATION OF AGREEMENT

REGARDING TRANSFER OF INTELLECTUAL AND PROPRIETARY RIGHTS TO PATENT(S)

1. PARTIES

Landegren Gene Technology AB, 556515-6725 hereinafter referred to as "the Company",

and

Ulf Landegren, 520608-1217, hereinafter referred to as "the Transferor".

2. BACKGROUND

- 2.1 The Company was set up to commercialize certain intellectual property rights belonging to the Transferor. The Transferor is a founder of the Company.
- 2.2 The Transferor possessed certain rights to patent(s)/patent application(s) as set out in <u>Exhibit 1</u>, hereinafter referred to as "the Patents".
- 2.2 During the period from February 14, 1996 until September 17, 2004, the Transferor transferred the rights to the IP as set out in Exhibit 1 to the Company in accordance with Exhibit 1.

3. CONFIRMATION OF ASSIGNMENT

- 3.1 This document is a confirmation of several assignment agreements (verbal and written) between the Transferor and the Company made during the period referred to in the previous section. According to the mentioned agreements, the Transferor irrevocably grants and assigns all rights in and to the Patents to the Company, as well as all results, improvements, discoveries or inventions that fall under the Patents or are related to the Patents ("Related IPR"). The assignment referred to in the previous phrase includes the right to sell, license or otherwise transfer the Patents or the Related IPR.
- 3.2 The Transferor also agreed to assist the Company in obtaining/maintaining patent rights and/or other intellectual property rights referring to the Patents and/or the Related IPR as long as this is possible under applicable law, and thereby sign such documents and take such other measures to create, maintain, transfer or otherwise dispose of the Patent(s) and/or the Related IPR, which is requested by the Company from time to time. This obligation shall survive the expiry/termination of this agreement. The costs and expenses connected with the procedures for obtaining and maintaining the Patent(s) and/or the Related IPR shall be borne by the Company.

4. TRANSFERORS WARRANTIES

4.1 The Transferor represents and warrants that its right to the Patent(s) and the Related IPR is complete and unrestricted.

5. COMPANYS RIGHTS TO ASSIGN THE TRANSFERRED IP RIGHTS

5.1 The Company have the unrestricted right to assign this entire agreement or separate IP rights received according to this agreement to a third party.

6. TERM

6.1 The obligations under section 3.2 above are valid as long as the Patens and/or the Related IPR are possible to protect under applicable law.

8

- 7. DISPUTE SETTLEMENT
- 7.1 This agreement shall be governed by and construed under the substantive laws of Sweden.
- 7.2 Any dispute, controversy or claim arising out of or in connection with this agreement, or regarding any legal relations arising out of or in connection therewith, shall be finally settled by arbitration in accordance with the rules of the Arbitration Institute of the Stockholm Chamber of Commerce. The Arbitration Tribunal shall be composed of one arbitrator appointed by the Arbitration Institute.

This agreement has been executed in two (2) identical copies, of which each of the parties has taken one.

Place: UNIMA

Date: DECEMBELL, 2006

LANDEGREN GENETECHNOLOGY AB

If Landepren

Place: UPSAL

Date: BECENOICIL, WOL

Ulf Landegren

Uppseh, December 11, 2006

MATS NILSSON +46(0)73 053 78 76

سولا

Patent id	Trivial name	Abstract
WO9522623	Padlock I	The invention relates to a method of detecting a target nucleic acid sequence in a
		sample by contacting the sample with a detectable probe to hybridize the probe to the
Patents		target sequence, and detecting the hybridized probe. The method comprises the steps
US5871921	· .	of: a) providing a detectable probe comprising two free nucleic acid end parts which
DE	ł	are capable of hybridizing to two at least substantially neighbouring regions of the
FR	j	target sequence, b) hybridizing the probe ends to the target sequence under hybridizing
GB]	conditions, c) convalently connecting the ends of the hybridized probe with each other
IT		to form a cyclized structure interlocking with the target molecule, d) subjecting the
NL CH	}	target sequence to non-hybridizing conditions and/or exonuclease activity to remove
Cn	İ	any non-cyclized probe from the target sequence, thereby retaining only the cyclized probe bound to the target molecule, e) optionally repeating steps b) to d) one or more
Application		times, and f) detecting the presence, and if desired, location of remaining labelled
JP	1	probe as indictative of the presence of the target nucleic acid sequence. The invention
{	[·	also relates to a detecting reagent or probe as well as a kit for use in the method.
		F F
1	1	he were
	Ì	
	4	Mile Mile
		T T X
	}	
		s de la
		LANDEGREN ULF (SE); KWIATKOWSKI MAREK (SE)
WO9741254	Padlock 2	The present invention relates to improved methods for probing of specific nucleic
į		acids using circularizable probes designed such that they report the presence of a target
Patents		sequence by allowing a detectable moiety to remain bound if and only if the probe has
CH		been cyclized in a target-dependent linking reaction. The invention may be used for
DE	ĺ	distinction between sequence specific variations of nucleic acids.
FR		(ANDECREALITE (OF)
GB	İ	LANDEGREN ULF (SE)
Applications	ļ	·
US	1	
JP		
CA	1	
}	<u> </u>	
WO9709069	Padlock 3	The present invention relates to methods and compositions for targeting nucleic acid
	,	sequences, more specifically double stranded nucleic acid sequences. The
Patents	1	compositions comprise oligonucleotides in the form of padlock probes. The padlock
DE		probes have two free nucleic acid end parts which are at least partially complementary
FR		to and capable of hybridizing with two at least substantially neighboring respective
GB	1	regions of a target nucleic acid sequence. Furthermore, the invention relates to use of
IT	1	said compositions as medicaments for treating genetic disorders.
NL	1	LANDEGREN ULF (SE)
SE		
Applications		
US		
WO9949079	Padlock 4	Rolling circle replication of a padlock primer is inhibited when it is hybridised to a
		target nucleic acid that is long or circular. The invention provides methods of
Patents	1	addressing this problem including cutting the target nucleic acid near or preferably at the site which hybridises with the padlock probe, whereby a 3'-end of the cut target
US6558928		

Appliactions US divisional 2003 CA		nucleic acid acts as a primer for rolling circle replication of the padlock probe. Also included is a method for assaying for a polyepitopic target by the use of two affinity probes each carrying an oligonucleotide tag and of padlock probe for rolling circle replication in association with the two affinity probes.
EP IP	÷	W 15 22 22 22 22 22 22 22 22 22 22 22 22 22
		12
WO03012119	Padlock 6	LANDEGREN ULF (SE) A nucleic acid amplification method, and probes for use within the method are described.
Patents Applications US CA EP JP		CLAIMS1. A method of analyzing circularized nucleic acids, by providing an amplification product, amplifying the said circularized DNA, which product comprises a concatemer of a sequence to be analyzed; the method further comprising the steps of: a) directly detecting the said amplification product in a homogenous hybridization reaction using singly-or ratio-labeled probes, wherein the said homogenous hybridization detection is based on an enrichment of the detection probes in the said amplification product, and/or by using a modified molecular beacon design; or - b) carrying out a further signal generating reaction, comprising at least one of the following: I) providing a degradable signaling probe that is selectively degraded when it has hybridized to the said amplification product, wherein degraded probes dissociate from the said amplification product allowing further signaling probes to hybridize with the product, wherein hybridization and degradation of the probes effects a change in signal emitted by the probe.
		GULLBERG MATS (SE); LANDEGREN ULF (SE); NILSSON MATS (SE)
WO03044229 Patents	Padlock 7	This invention relates to methods, reagents and kits for enriching nucleic acid sequences. More particularly, the present invention relates to methods, reagents and kits for sample preparation including sample modification, sample enrichment and amplification
Applications US EP GB		CLAIMS 1. A method of enriching a preselected nucleic acid segment from a mixture of nucleic acid sequences, the preselected nucleic acid sequence encompassing a specific variant at a given position, the method comprising the steps of: (a) providing a nucleic acid mixture of sequences which includes the preselected nucleic acid segment to be enriched; (b) cleaving the nucleic acid sequences in the mixture to provide a nucleic acid fragment comprising the preselected nucleic acid segment; (c) providing a template oligonucleotide, one end of which hybridises to a sequence of the segment at or close to the variant position, and the other end of which hybridises to the end of a protecting sequence; (d) hybridising the template to the nucleic acid segment and to the protecting sequence such that the variant position and the end of the protecting sequence are brought into proximity of each other; (e) joining the end of the protecting sequence to the nucleic acid segment to form a ligated product, which ligated product is protected from degradation; and (f) enriching for the ligated sequence.
		GULLBERG MATS (SE); LANDEGREN ULF (SE)
WO9700446 Patents DE69614539	Prox 1	The present invention relates to an immunological test kit and immunoassay using a first immobilized antibody having affinity for a specific antigen. The invention is characterized by a second and third antibody being specific for different determinants of the antigen and modified with cross-linkable oligonucleotides. For detection, the
D AU702125 SE0504798		oligonucleotides are amplified, whereby only such oligonucleotides will be amplified which have been cross-linked to each other. In this way unspecific background is avoided and detection is possible down to single molecules.

CH FR GB IT Applications US CA JP		
WO0161037 Patents SE Applications US AU CA EP JP	Prox 2	LANDEGREN ULF (SE) The present invention relates to sensitive, rapid and convenient assays for detection and/or quantification of one or several analyte(s) in solution using so called proximity probes. The proximity probes comprise a binding moiety and a nucleic acid. The nucleic acid from one proximity probe is only capable of interaction with the nucleic acid from the other proximity probe when these are in close proximity, i.e. have bound to the analytes for which they are specific. The present Invention relates to methods and kits for proximity probing and are performed in solution without the need of a solid phase. FREDRIKSSON SIMON (SE); LANDEGREN ULF (SE)